Published in Vaccine Weekly, November 27th, 2002
The vaccine consists of a highly purified protein, protective antigen. Using recombinant technology and advanced production processes acquired from Avant Immunotherapeutics, Inc. (AVAN), DVC hopes this vaccine will offer a safe, effective product to support the country's need for a new-generation anthrax vaccine.
The phase I trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in conjunction with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly